Comprehensive and deep profiling of the plasma proteome with protein corona on zeolite NaY

Congcong Ma; Yanwei Li; Jie Li; Lei Song; Liangyu Chen; Na Zhao; Xueping Li; Ning Chen; Lixia Long; Jin Zhao; Xin Hou; Li Ren; Xubo Yuan

doi:10.1016/j.jpha.2023.04.002

Volume 13 Issue 5

May 2023

Turn off MathJax

Article Contents

Article Navigation > Journal of Pharmaceutical Analysis > 2023 > 13(5): 503-513

Congcong Ma, Yanwei Li, Jie Li, Lei Song, Liangyu Chen, Na Zhao, Xueping Li, Ning Chen, Lixia Long, Jin Zhao, Xin Hou, Li Ren, Xubo Yuan. Comprehensive and deep profiling of the plasma proteome with protein corona on zeolite NaY[J]. Journal of Pharmaceutical Analysis, 2023, 13(5): 503-513. doi: 10.1016/j.jpha.2023.04.002

Citation:

Congcong Ma, Yanwei Li, Jie Li, Lei Song, Liangyu Chen, Na Zhao, Xueping Li, Ning Chen, Lixia Long, Jin Zhao, Xin Hou, Li Ren, Xubo Yuan. Comprehensive and deep profiling of the plasma proteome with protein corona on zeolite NaY[J]. Journal of Pharmaceutical Analysis, 2023, 13(5): 503-513. doi: 10.1016/j.jpha.2023.04.002

Citation:

Congcong Ma, Yanwei Li, Jie Li, Lei Song, Liangyu Chen, Na Zhao, Xueping Li, Ning Chen, Lixia Long, Jin Zhao, Xin Hou, Li Ren, Xubo Yuan. Comprehensive and deep profiling of the plasma proteome with protein corona on zeolite NaY[J]. Journal of Pharmaceutical Analysis, 2023, 13(5): 503-513. doi: 10.1016/j.jpha.2023.04.002

PDF( 2526 KB)

Comprehensive and deep profiling of the plasma proteome with protein corona on zeolite NaY

doi: 10.1016/j.jpha.2023.04.002

a. Tianjin Key Laboratory of Composite and Functional Materials, School of Materials Science and Engineering, Tianjin University, Tianjin, 300350, China;
b. Department of Integrative Oncology, Tianjin Medical University Cancer Institute and Hospital and Key Laboratory of Cancer Prevention and Therapy, Tianjin, 300060, China;
c. Department of Proteomics, Tianjin Key Laboratory of Clinical Multi-omics, Tianjin, 300308, China;
d. Department of Clinical Laboratory, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, 300060, China

Funds:

This work was supported by the National Natural Science Foundation of China (Grant No: 51773151).

Received Date: Jan. 03, 2023
Accepted Date: Apr. 06, 2023
Rev Recd Date: Mar. 27, 2023
Publish Date: Apr. 12, 2023

Abstract

Abstract

Proteomic characterization of plasma is critical for the development of novel pharmacodynamic biomarkers. However, the vast dynamic range renders the profiling of proteomes extremely challenging. Here, we synthesized zeolite NaY and developed a simple and rapid method to achieve comprehensive and deep profiling of the plasma proteome using the plasma protein corona formed on zeolite NaY. Specifically, zeolite NaY and plasma were co-incubated to form plasma protein corona on zeolite NaY (NaY-PPC), followed by conventional protein identification using liquid chromatography-tandem mass spectrometry. NaY was able to significantly enhance the detection of low-abundance plasma proteins, minimizing the “masking” effect caused by high-abundance proteins. The relative abundance of middle- and low-abundance proteins increased substantially from 2.54% to 54.41%, and the top 20 high-abundance proteins decreased from 83.63% to 25.77%. Notably, our method can quantify approximately 4000 plasma proteins with sensitivity up to pg/mL, compared to only about 600 proteins identified from untreated plasma samples. A pilot study based on plasma samples from 30 lung adenocarcinoma patients and 15 healthy subjects demonstrated that our method could successfully distinguish between healthy and disease states. In summary, this work provides an advantageous tool for the exploration of plasma proteomics and its translational applications.
- NaY,
- Plasma proteomics,
- Protein corona,
- Low-abundance proteins

FullText(HTML)

References(56)

References

L.A. Liotta, M. Ferrari, E. Petricoin, Clinical proteomics: Written in blood, Nature 425 (2003), 905.

N.L. Anderson, N.G. Anderson, The human plasma proteome: History, character, and diagnostic prospects, Mol. Cell. Proteomics 1 (2002) 845–867.

M. Pernemalm, J. Lehtiö, Mass spectrometry-based plasma proteomics: State of the art and future outlook, Expert Rev. Proteom. 11 (2014) 431–448.

P.E. Geyer, N.A. Kulak, G. Pichler, et al., Plasma proteome profiling to assess human health and disease, Cell Syst. 2 (2016) 185–195.

M. Hadjidemetriou, Z. Al-Ahmady, M. Buggio, et al., A novel scavenging tool for cancer biomarker discovery based on the blood-circulating nanoparticle protein corona, Biomaterials 188 (2019) 118–129.

R. Pieper, Q. Su, C.L. Gatlin, et al., Multi-component immunoaffinity subtraction chromatography: An innovative step towards a comprehensive survey of the human plasma proteome, Proteomics 3 (2003) 422–432.

W.-J. Qian, D.T. Kaleta, B.O. Petritis, et al., Enhanced detection of low abundance human plasma proteins using a tandem IgY12-SuperMix immunoaffinity separation strategy, Mol. Cell. Proteomics 7 (2008) 1963–1973.

T. Shi, J.-Y. Zhou, M.A. Gritsenko, et al., IgY14 and SuperMix immunoaffinity separations coupled with liquid chromatography–mass spectrometry for human plasma proteomics biomarker discovery, Methods 56 (2012) 246–253.

E.C. Keilhauer, M.Y. Hein, M. Mann, Accurate protein complex retrieval by affinity enrichment mass spectrometry (AE-MS) rather than affinity purification mass spectrometry (AP-MS), Mol. Cell. Proteomics 14 (2015) 120–135.

J. Granger, J. Siddiqui, S. Copeland, et al., Albumin depletion of human plasma also removes low abundance proteins including the cytokines, Proteomics 5 (2005) 4713–4718.

E. Bellei, S. Bergamini, E. Monari, et al., High-abundance proteins depletion for serum proteomic analysis: Concomitant removal of non-targeted proteins, Amino Acids 40 (2011) 145–156.

H. Keshishian, M.W. Burgess, H. Specht, et al., Quantitative, multiplexed workflow for deep analysis of human blood plasma and biomarker discovery by mass spectrometry, Nat. Protoc. 12 (2017) 1683–1701.

T. Cedervall, I. Lynch, S. Lindman, et al., Understanding the nanoparticle-protein corona using methods to quantify exchange rates and affinities of proteins for nanoparticles, Proc. Natl. Acad. Sci. USA. 104 (2007) 2050–2055.

M. Lundqvist, J. Stigler, T. Cedervall, et al., The evolution of the protein corona around nanoparticles: A test study, ACS Nano 5 (2011) 7503–7509.

M.P. Monopoli, D. Walczyk, A. Campbell, et al., Physical-chemical aspects of protein corona: relevance to in vitro and in vivo biological impacts of nanoparticles, J. Am. Chem. Soc. 133 (2011) 2525–2534.

D. Caputo, M. Papi, R. Coppola, et al., A protein corona-enabled blood test for early cancer detection, Nanoscale 9 (2017) 349–354.

N. Deng, Y. Chen, B. Jiang, et al., A robust and effective intact protein fractionation strategy by GO/PEI/Au/PEG nanocomposites for human plasma proteome analysis, Talanta 178 (2018) 49–56.

F. Perona Martinez, A. Nagl, S. Guluzade, et al., Nanodiamond for sample preparation in proteomics, Anal. Chem. 91 (2019) 9800–9805.

J.E. Blume, W.C. Manning, G. Troiano, et al., Rapid, deep and precise profiling of the plasma proteome with multi-nanoparticle protein corona, Nat. Commun. 11 (2020), 3662.

S. Ferdosi, B. Tangeysh, T.R. Brown, et al., Engineered nanoparticles enable deep proteomics studies at scale by leveraging tunable nano-bio interactions, Proc. Natl. Acad. Sci. U. S. A 119 (2022), e2106053119.

Y. Liu, Q. Yang, Z. Du, et al., Synthesis of surface-functionalized molybdenum disulfide nanomaterials for efficient adsorption and deep profiling of the human plasma proteome by data-independent acquisition, Anal. Chem. 94 (2022) 14956–14964.

Y. Meng, J. Chen, Y. Liu, et al., A highly efficient protein corona-based proteomic analysis strategy for the discovery of pharmacodynamic biomarkers, J. Pharm. Anal. 12 (2022) 879–888.

E.A. Ponomarenko, E.V. Poverennaya, E.V. Ilgisonis, et al., The size of the human proteome: the width and depth, Int. J. Anal. Chem. 2016 (2016), 7436849.

N.L. Anderson, A.S. Ptolemy, N. Rifai, The riddle of protein diagnostics: Future bleak or bright?, Clin. Chem. 59 (2013) 194–197.

E. Pérez-Botella, S. Valencia, F. Rey, Zeolites in adsorption processes: State of the art and future prospects, Chem. Rev. 122 (2022) 17647–17695.

A. Corma, State of the art and future challenges of zeolites as catalysts, J. Catal. 216 (2003) 298–312.

J. Wu, X. Li, Y. Yan, et al., Protein adsorption onto nanozeolite: Effect of micropore openings, J. Colloid Interface Sci. 406 (2013) 130–138.

M. Rahimi, E.-P. Ng, K. Bakhtiari, et al., Zeolite nanoparticles for selective sorption of plasma proteins, Sci. Rep. 5 (2015), 17259.

M. Matsui, Y. Kiyozumi, T. Yamamoto, et al., Selective adsorption of biopolymers on zeolites, Chemistry 7 (2001) 1555–1560.

Y. Zhang, X. Wang, W. Shan, et al., Enrichment of low-abundance peptides and proteins on zeolite nanocrystals for direct MALDI-TOF MS analysis, Angew. Chem. Int. Ed. Engl. 44 (2005) 615–617.

Y. Huang, K. Wang, D. Dong, et al., Synthesis of hierarchical porous zeolite NaY particles with controllable particle sizes, Microporous Mesoporous Mater. 127 (2010) 167–175.

A. Charkhi, M. Kazemeini, S.J. Ahmadi, et al., Fabrication of granulated NaY zeolite nanoparticles using a new method and study the adsorption properties, Powder Technol. 231 (2012) 1–6.

N. Bu, X. Liu, S. Song, et al., Synthesis of NaY zeolite from coal gangue and its characterization for lead removal from aqueous solution, Adv. Powder Technol. 31 (2020) 2699–2710.

M. Kalhor, Z. Zarnegar, Fe₃O₄/SO₃H@zeolite-Y as a novel multi-functional and magnetic nanocatalyst for clean and soft synthesis of imidazole and perimidine derivatives, RSC Adv. 9 (2019) 19333–19346.

S. Winzen, S. Schoettler, G. Baier, et al., Complementary analysis of the hard and soft protein corona: Sample preparation critically effects corona composition, Nanoscale 7 (2015) 2992–3001.

C. Corbo, A.A. Li, H. Poustchi, et al., Analysis of the human plasma proteome using multi-nanoparticle protein corona for detection of alzheimer's disease, Adv. Healthc. Mater. 10 (2021), 2000948.

G. Such- Sanmartín, E. Ventura-Espejo, O.N. Jensen, Depletion of abundant plasma proteins by poly(N-isopropylacrylamide-acrylic acid) hydrogel particles, Anal. Chem. 86 (2014) 1543–1550.

H. Keshishian, M.W. Burgess, M.A. Gillette, et al., Multiplexed, quantitative workflow for sensitive biomarker discovery in plasma yields novel candidates for early myocardial injury, Mol. Cell. Proteomics 14 (2015) 2375–2393.

J.P.F. Bai, J.S. Barrett, G.J. Burckart, et al., Strategic biomarkers for drug development in treating rare diseases and diseases in neonates and infants, AAPS J. 15 (2013) 447–454.

G.L. Hortin, D. Sviridov, N.L. Anderson, High-abundance polypeptides of the human plasma proteome comprising the top 4 logs of polypeptide abundance, Clin. Chem. 54 (2008) 1608–1616.

U. Sakulkhu, M. Mahmoudi, L. Maurizi, et al., Significance of surface charge and shell material of superparamagnetic iron oxide nanoparticle (SPION) based core/shell nanoparticles on the composition of the protein corona, Biomater. Sci. 3 (2015) 265–278.

D. Bonvin, U. Aschauer, D.T.L. Alexander, et al., Protein Corona: Impact of lymph versus blood in a complex in vitro environment, Small (2017), 1700409.

S. Tenzer, D. Docter, J. Kuharev, et al., Rapid formation of plasma protein corona critically affects nanoparticle pathophysiology, Nat. Nanotechnol. 8 (2013) 772–781.

S. Ferdosi, A. Stukalov, M. Hasan, et al., Enhanced competition at the nano-bio interface enables comprehensive characterization of protein corona dynamics and deep coverage of proteomes, Adv. Mater. 34 (2022), 2206008.

L. Vroman, A.L. Adams, G.C. Fischer, et al., Interaction of high molecular weight kininogen, factor XII, and fibrinogen in plasma at interfaces, Blood 55 (1980) 156–159.

E.W. Deutsch, G.S. Omenn, Z. Sun, et al., Advances and utility of the human plasma proteome, J. Proteome Res. 20 (2021) 5241–5263.

J.M. Schwenk, G.S. Omenn, Z. Sun, et al., The human plasma proteome draft of 2017: building on the human plasma peptideAtlas from mass spectrometry and complementary assays, J. Proteome Res. 16 (2017) 4299-4310.

J.M. Schwenk, G.S. Omenn, Z. Sun, et al., The human plasma proteome draft of 2017: Building on the human plasma PeptideAtlas from mass spectrometry and complementary assays, J. Proteome Res. 16 (2017) 4299–4310.

F. Bray, J. Ferlay, I. Soerjomataram, et al., Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CAA Cancer J. Clin. 68 (2018) 394–424.

X. Li, Y. Shi, Z. Yin, et al., An eight-miRNA signature as a potential biomarker for predicting survival in lung adenocarcinoma, J. Transl. Med. 12 (2014), 159.

H. Jang, Y. Jun, S. Kim, et al., FCN₃ functions as a tumor suppressor of lung adenocarcinoma through induction of endoplasmic reticulum stress, Cell Death Dis. 12 (2021), 407.

S.A. Best, S. Ding, A. Kersbergen, et al., Distinct initiating events underpin the immune and metabolic heterogeneity of KRAS-mutant lung adenocarcinoma, Nat. Commun. 10 (2019), 4190.

S. Zhu, W. Chen, J. Wang, et al., SAM68 promotes tumorigenesis in lung adenocarcinoma by regulating metabolic conversion via PKM alternative splicing, Theranostics 11 (2021) 3359–3375.

T. Huang, P. Zhang, W. Li, et al., G9A promotes tumor cell growth and invasion by silencing CASP1 in non-small-cell lung cancer cells, Cell Death Dis. 8 (2017), e2726.

F. Li, H. Yang, T. Kong, et al., PGAM1, regulated by miR-3614-5p, functions as an oncogene by activating transforming growth factor-β (TGF-β) signaling in the progression of non-small cell lung carcinoma, Cell Death Dis. 11 (2020), 710.

J.-Y. Xu, C. Zhang, X. Wang, et al., Integrative proteomic characterization of human lung adenocarcinoma, Cell 182 (2020) 245–261.e17.

Relative Articles

Supplements(0)

Cited By

Proportional views